More articles from 2010s

You have access
Prostate-Specific Membrane Antigen: The Target of the Decade, from Biochemical Recurrence to Widespread Adoption (perspective on “Evaluation of hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy” J Nucl Med. 2015;56:668–674)
Michael S. Hofman

Journal of Nuclear Medicine December 1, 2020, 61 (Supplement 2) 246S-254S; DOI: https://doi.org/10.2967/jnumed.120.252213
You have access
A Stepping-Stone to Fully Integrated Whole-Body PET/MRI (perspective on “Performance Measurements of the Siemens mMR Integrated Whole-Body PET/MR Scanner” J Nucl Med. 2011;52:1914–1922)
Ciprian Catana

Journal of Nuclear Medicine December 1, 2020, 61 (Supplement 2) 236S-245S; DOI: https://doi.org/10.2967/jnumed.120.252239
You have access
From Compassionate Use to Phase 3 Trial: The Impact of Germany’s PSMA-617 Literature (perspective on “German Multicenter Study Investigating ¹⁷⁷Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients” J Nucl Med. 2017;58:85–90)
Thomas A. Hope

Journal of Nuclear Medicine December 1, 2020, 61 (Supplement 2) 255S-262S; DOI: https://doi.org/10.2967/jnumed.120.252122
You have access
Switching on Brain PET to Light Up Amyloid Pathology In Vivo (perspective on “In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand ¹⁸F-AV-45 (Florbetapir F 18)” J Nucl Med. 2010;51:913–920)
Henryk Barthel

Journal of Nuclear Medicine December 1, 2020, 61 (Supplement 2) 227S-235S; DOI: https://doi.org/10.2967/jnumed.120.251900